Table 1.

Description of the study cohort (N = 1038).

Features			Features
Age at diagnosis	N	%	HER2 Status	N	%
20–39	100	9.6	Negative	762	81.0
40–59	530	51.1	Positive	163	17.3
60–79	384	37.0	Undetermined	17	1.7
80–99	24	2.3	Missing	96
Menopausal Status			Tumor Subtype
Premenopausal	303	30.0	Luminal A	544	57.0
Postmenopausal	712	70.0	Luminal B	210	22.2
Missing	23		HER2-like	64	6.7
			Triple-Negative	135	14.1
Histopathological Type			Missing	85
Ductal Invasive	902	87.0
Lobular Invasive	58	5.6	rs699947
In situ (ductal or lobular)	49	4.6	CC	402	45.3
Others	29	2.8	CA	379	42.7
			AA	106	12.0
Tumor Size (T)			Missing	151
Tis	48	4.7
T1 (< 2cm)	342	33.7	rs833061
T2 (2cm – 5cm)	472	46.5	TT	308	35.1
T3 (> 5cm)	152	15.0	TC	436	49.7
Missing	24		CC	133	15.2
			Missing	161
Lymph Node Status
Negative	491	48.1	rs1570360
Positive	529	51.9	GG	507	60.1
Missing	18		GA	279	33.0
			AA	58	6.9
Tumor Stage (TNM)			Missing	194
≤ IIA	862	85.0
≥ IIB	152	15.0	rs2010963
Missing	24		GG	365	41.5
			GC	403	45.8
Tumor Grade (G)			CC	112	12.7
G1	96	11.1	Missing	158
G2	403	46.5
G3	367	42.4	rs3025039
Missing	172		CC	660	75.2
			CT	205	23.3
ER Status			TT	13	1.5
Negative	211	20.8	Missing	160
Positive	800	79.2
Missing	27		Haplotypea
			*1 CTGG	435	24.4
PR Status			*2 CTGC	602	33.8
Negative	348	34.6	*3 ACAG	363	20.4
Positive	658	65.4	*4 ACGG	208	11.7
Missing	32		*5 CCGG	96	5.4
			Others	76	4.3

^aVEGFA haplotypes composed by rs699947, rs833061, rs1570360, rs2010963

Abbreviations: ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2.